ClinicalTrials.gg
RecruitingNCT06807190Updated Aug 27, 2026

General Use-results Surveillance With Awiqli in Patients With Diabetes Mellitus

An observational study in Diabetes Mellitus, Type 1, sponsored by Novo Nordisk A/S. Recruiting at 116 sites in Japan. Per ClinicalTrials.gov, last updated 2026-08-27.

Sponsored by Novo Nordisk A/S · Observational

How we know

From the registry’s dates

  • Started Apr 2025; still recruiting 1 year 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
630
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 226 studies in Diabetes Mellitus, Type 1 by Novo Nordisk A/S — 2 open to participants now, 5 under way, 1 of them phase 3. Diabetes Mellitus, Type 1 · Novo Nordisk A/S.

Planned enrollment
54th of 77
630 · median 1,068
Started
2025
with 6 others
Observational
77 of 226
1 open now
Registered
219th of 226
by date

Among the 226 studies in Diabetes Mellitus, Type 1 by Novo Nordisk A/S, this one is the 54th largest by planned enrollment of the 77 observational ones that give a count, is one of 7 that started in 2025, is one of 77 observational ones, and was the 219th registered.

Diabetes Mellitus, Type 1

3,758 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.

Browse Diabetes Mellitus, Type 1 studies →

Open to participants now

2 of the 226 studies in Diabetes Mellitus, Type 1 by Novo Nordisk A/S are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 417 Diabetes Mellitus, Type 1 studies recruiting now, 130 (31%) set no upper age limit and 261 (63%) stop at 75 or younger; 187 take children under 18; 66 take healthy volunteers.

This study: all sexes.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 226 studies in Diabetes Mellitus, Type 1 by Novo Nordisk A/S, or all of them as a file.
02

Study summary

The purpose of the study is to investigate the safety and effectiveness of Awiqli in participants with diabetes mellitus under real world clinical practice in Japan. Participants will get Awiqli as prescribed by the study doctor. The study will last for about 1 year.

03

Conditions studied

  • Diabetes Mellitus, Type 1
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Sampling method
Non-probability sample

Study population

The study population comprises patients who are diagnosed with diabetes mellitus and who agree to be treated with Awiqli after consultation with their physician independently from the decision to participate in this study.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed consent obtained before any study-related activities (study-related activities are any procedure related to recording of data according to the protocol).
  • The decision to initiate treatment with commercially available Awiqli has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician before and independently from the decision to include the patient in this study.
  • Male or female with no age limitation.
  • Diagnosis of diabetes mellitus. There is no limitation for type of diabetes mellitus and prior treatment for diabetes mellitus.

Exclusion criteria

Exclusion Criteria:

  • Previous participation in this study. Participation is defined as having given in this study.
  • Treatment with any drug within 30 days prior to enrolment into the study.
  • Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation.
  • described in Japanese package insert.
  • Participants showing hypoglycaemic symptoms.
  • Participants with a history of to any ingredients of this drug.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
630 participants (estimated)
Patient registry
No

Groups and cohorts

  • Awiqli

    Participants with diabetes mellitus will be treated with commercially available Awiqli according to routine clinical practice at the discretion of the treating physician.

    Drug: Insulin Icodec

Interventions

  • Participants will be treated with commercially available Awiqli according to routine clinical practice at the discretion of the treating physician.

    Also known as: Awiqli

06

What researchers measure

Primary outcomes

  1. Number of Adverse Reactions (ARs)

    Measured as number of events.

    Time frame: From baseline (week 0) to end of study (week 52)

Secondary outcomes

  1. Number of Adverse Events (AEs)

    Measured as number of events.

    Time frame: From baseline (week 0) to end of study (week 52)

  2. Number of Serious Adverse Events (SAEs)

    Measured as number of events.

    Time frame: From baseline (week 0) to end of study (week 52)

  3. Number of Serious Adverse Reactions (SARs)

    Measured as number of events.

    Time frame: From baseline (week 0) to end of study (week 52)

  4. Change in Glycosylated Haemoglobin (HbA1c)

    Measured as percentage (%) point of HbA1c.

    Time frame: From baseline (week 0) to end of study (week 52)

  5. Change in Fasting Plasma Glucose (FPG)

    Measured as milligrams per decilitre (mg/dL).

    Time frame: From baseline (week 0) to end of study (week 52)

  6. Change in Diabetes Therapy-Related Quality Of Life (DTR-QOL)

    DTR-QOL is a Japanese questionnaire assessing the influence of diabetes treatment on the individual health related quality of life on 4 domains: "burden on social activities and daily activities", "anxiety and dissatisfaction with treatment", "hypoglycaemia" and "satisfaction with treatment". DTR-QOL contains 29 questions and the response scale is a 7-point scale (1: strongly agree to 7: strongly disagree). The score of each item will be reversed so that "7: strongly disagree" represents the highest/desirable QOL. The total score, after simple addition of the item scores, is converted to 0 to 100 (best-case response is 100; worst case response is 0).

    Time frame: From baseline (week 0) to end of study (week 52)

07

Study locations

114 of 116 sites recruiting
  • Seino Internal Medicine Clinic_Internal medicine
    Koriyama-shi, Fukushima, Fukushima, Japan 963-8851, Japan
    Recruiting
  • Abe Diabetes Clinic_Internal Medicine
    Oita-shi, Oita,, Japan 870 0039, Japan
    Enrolling by invitation
  • Jinnouchi Hospital_Internal Medicine
    Kumamoto, Kumamoto, Japan 862-0976, Japan
    Recruiting
  • Miyachi Clinic
    Aichi, 448-0852, Japan
    Recruiting
  • Clinic Tosaki
    Aichi, 468-0009, Japan
    Recruiting
  • Fukuoka Naika Clinic_Internal Medicine
    Aichi, 470-0126, Japan
    Enrolling by invitation
  • Hattori Clinic Chiryu_Diabetes and Endocrinology
    Aichi, 472-0053, Japan
    Enrolling by invitation
  • Uenishi Internal Medicine Clinic
    Aichi, 485-0044, Japan
    Recruiting
  • Inazawa Municipal Hospital_Diabetes and Endocrinology
    Aichi, 492-8510, Japan
    Enrolling by invitation
  • Ichinomiyanishi Hospital
    Aichi, 494-0001, Japan
    Enrolling by invitation
  • Ohisama Clinic_Aomori
    Aomori, 030-0823, Japan
    Enrolling by invitation
  • Kakizaki Tonyobyo Naika Clinic
    Aomori, 038-0011, Japan
    Recruiting
  • Chiba Central Medical Center
    Chiba, 264-0017, Japan
    Enrolling by invitation
  • Shinmatsudo Central General Hospital_Diabetes and Endocrinology
    Chiba, 270-0034, Japan
    Enrolling by invitation
  • Kimitsu Chuo Hospital_Diabetology and Endocrinology
    Chiba, 292-0822, Japan
    Recruiting
  • Hasegawa Medicine Clinic, Internal medicine
    Chitose, Hokkaido, 066-0032, Japan
    Not yet recruiting
  • Soyokaze CardioVascular Medicine and Diabetes Care
    Ehime, 790-0026, Japan
    Enrolling by invitation
  • Kyushu Rosai Hospital_Diabetes and Metabolism
    Fukuoka, 800-0296, Japan
    Enrolling by invitation
  • Kokura Memorial Hospital_Diabetes and Endocrinology
    Fukuoka, 802-8555, Japan
    Enrolling by invitation
  • Kitakyushu Municipal Medical Center_Endocrinology and Diabetes
    Fukuoka, 802-8561, Japan
    Enrolling by invitation
  • Steel Memorial Yawata Hospital_Diabetes Internal Medicine
    Fukuoka, 805-8508, Japan
    Enrolling by invitation
  • Okada Naika Clinic
    Fukuoka, 812-0053, Japan
    Enrolling by invitation
  • Fukuoka Kieikai Hospital_Diabetes and obesity centre
    Fukuoka, 813-0044, Japan
    Enrolling by invitation
  • Clinic Masae Minami
    Fukuoka, 815-0071, Japan
    Recruiting
  • Ito Naika Clinic_Internal Medicine
    Fukuoka, 818-0024, Japan
    Recruiting
  • Tanaka Naika Clinic_Internal Medicine
    Fukuoka, 830-0023, Japan
    Enrolling by invitation
  • Gifu University Hospital_Diabetes and Endocrinology
    Gifu, 501-1194, Japan
    Enrolling by invitation
  • Asano Naika
    Gifu, 504-0829, Japan
    Enrolling by invitation
  • Shimizu Naika
    Gunma, 370-0069, Japan
    Enrolling by invitation
  • Gunma University Hospital_Endocrinology and Diabetes
    Gunma, 371-8511, Japan
    Enrolling by invitation
  • Murakami Memorial Hospital_Diabetes Internal Medicine
    Hiroshima, 722-0014, Japan
    Enrolling by invitation
  • Kurihara Naika
    Hokkaido, 004-0053, Japan
    Enrolling by invitation
  • Takasawa Diabetes Clinic
    Hokkaido, 041-0821, Japan
    Enrolling by invitation
  • Ito Hiroshi Naika Tonyobyonaika Clinic
    Hokkaido, 064-0824, Japan
    Enrolling by invitation
  • Yoshimura Tonyobyo Clinic
    Hokkaido, 068-0021, Japan
    Enrolling by invitation
  • Kagetsu Clinic
    Hokkaido, 073-1105, Japan
    Enrolling by invitation
  • Takabe Diabetes Clinic
    Hyogogoken, 670-0837, Japan
    Enrolling by invitation
  • Kagayaki Diabetes and Endocrinology Clinic Sannomiya_Diabetes Internal Medicine
    Hyōgo, 651-0086, Japan
    Enrolling by invitation
  • Matsuda Diabetes Clinic
    Hyōgo, 651-2135, Japan
    Recruiting
  • Hyogo Prefectural Awaji Medical Center_Diabetes and Endocrinology
    Hyōgo, 656-0021, Japan
    Enrolling by invitation
  • Ushiku Aiwa General Hospital_Diabetes and Metabolism
    Ibaraki, 300-1296, Japan
    Enrolling by invitation
  • Itabashi Diabetes and Dermatology Medical Clinic
    Ibaraki, 306-0232, Japan
    Enrolling by invitation
  • Naka Kinen Clinic_Internal medicine
    Ibaraki, 311-0113, Japan
    Enrolling by invitation
  • Mitoyo General Hospital_Internal Medicine
    Kagawa, 769-1695, Japan
    Enrolling by invitation
  • Tempozan Clinic of Internal Medicine
    Kagoshima-shi, Kagoshima, 890-0061, Japan
    Enrolling by invitation
  • Teikyo Univ.HP, Mizonokuchi_Fourth Internal Medicine
    Kanagawa, 213-8507, Japan
    Enrolling by invitation
  • Yokohama Rosai Hospital_Diabetes and Endocrinology
    Kanagawa, 222-0036, Japan
    Enrolling by invitation
  • Hiyoshi Clinic_Diabetes Internal Medicine
    Kanagawa, 223-0062, Japan
    Enrolling by invitation
  • H.E.C Science Clinic_Internal Medicine, Diabetes
    Kanagawa, 235-0045, Japan
    Enrolling by invitation
  • Kikuchi Naika Clinic_Kanagawa
    Kanagawa, 236-0033, Japan
    Recruiting
  • Shonanisehara Clinic_Internal Medicine
    Kanagawa, 259-1114, Japan
    Enrolling by invitation
  • Takeda Clinic
    Kanagawa, 259-1131, Japan
    Enrolling by invitation
  • Tokai University Hospital_Nephrology, Endocrinology and Metabolism
    Kanagawa, 259-1193, Japan
    Enrolling by invitation
  • Hotaruno hakuyukai Medical Corporation of Japan
    Kisarazu-shi, Chiba, 292-0038, Japan
    Recruiting
  • Kumamoto University Hospital, Diabetes, Metabo and Endo
    Kumamoto-shi, Kumamoto, 860-0811, Japan
    Enrolling by invitation
  • Kamiuchi Naika Clinic
    Kyoto, 604-8416, Japan
    Enrolling by invitation
  • Kyoto University Hospital_Department of Diabetes, Endocr
    Kyoto-shi, Kyoto, 606-8507, Japan
    Enrolling by invitation
  • Mie National Hospital_Internal Medicine
    Mie, 514-0125, Japan
    Enrolling by invitation
  • MG Clinic
    Mie, 516-0035, Japan
    Enrolling by invitation
  • Japanese Red Cross Ise Hospital_Diabetes and Metabolism
    Mie, 516-8512, Japan
    Enrolling by invitation
  • Kanno Naika_Internal Medicine
    Mitaka-shi, Tokyo, 181-0013, Japan
    Recruiting
  • Heiwadai Hospital_Diabetes and Internal Medicine
    Miyazaki, 880-0034, Japan
    Enrolling by invitation
  • Ato internal medicine clinic, internal medicine
    Muroran-shi, Hokkaido, 050-0073, Japan
    Enrolling by invitation
  • Asama General Hospital_Diabetology
    Nagano, 385-8558, Japan
    Enrolling by invitation
  • Minamiminowa Clinic_Internal Medicine and Endocrinology and Metabolism
    Nagano, 399-4511, Japan
    Enrolling by invitation
  • Sasebo City General Hospital_Diabetes and Endocrinology
    Nagasaki, 857-8511, Japan
    Enrolling by invitation
  • Kuriya Clinic_Diabetes and Internal Medicine
    Nagasaki, 859-3242, Japan
    Enrolling by invitation
  • Minagawa Clinic Internal Medicine
    Niigata, 942-0052, Japan
    Enrolling by invitation
  • Niigata Diabetes Clinic_Diabetes and Endocrinology
    Niigata, 950-1101, Japan
    Enrolling by invitation
  • Kitakamiekimae Naika Clinic
    Numakunai, 024-0061, Japan
    Recruiting
  • Okayama Medical Center_Diabetes and Endocrinology
    Okayama, 701-1192, Japan
    Enrolling by invitation
  • Chibana Clinic
    Okinawa, 904-2143, Japan
    Enrolling by invitation
  • Osaka General Hospital of West Japan Railway Company_Diabetes and Metabolism
    Osaka, 545-0053, Japan
    Recruiting
  • Kansai Electric Power Hospital_Center for Diabetes
    Osaka, 553-0003, Japan
    Enrolling by invitation
  • Osaka General Medical Center_Diabetes and Endocrinology
    Osaka, 558-8558, Japan
    Enrolling by invitation
  • Takatsuki General Hospital_Diabetes and Endocrinology
    Osaka, 569-1192, Japan
    Enrolling by invitation
  • Kansai Medical University Medical Center_Cardiology and Endocrinology and Metabolism
    Osaka, 570-8507, Japan
    Enrolling by invitation
  • Ogawa Clinic
    Osaka, 581-0869, Japan
    Recruiting
  • Matsuda Gastroenterology and Diabetes Clinic_Internal Medicine
    Osaka, 591-8006, Japan
    Recruiting
  • Japan Organization of Occupational Health and Safety Osaka Rosai Hospital_Diabetes Internal Medicine
    Osaka, 5918025, Japan
    Enrolling by invitation
  • Okamoto Clinic for Diabetes and Endocrinology
    Ōita, 879-7301, Japan
    Recruiting
  • Saga Chuo Public Hospital_Diabetes Internal Medicine
    Saga, 846-0012, Japan
    Enrolling by invitation
  • Imari Arita Kyoritsu Hospital_Internal Medicine
    Saga, 849-4193, Japan
    Recruiting
  • Saitama Medical Center_Diabetes and Endocrinology
    Saitama, 330-0074, Japan
    Enrolling by invitation
  • Japanese Red Cross Saitama Hospital_Diabetes and Endocrinology
    Saitama, 330-8553, Japan
    Enrolling by invitation
  • Higashisakado Clinic_Diabetes Internal Medicine
    Saitama, 350-0205, Japan
    Enrolling by invitation
  • Asano Clinic
    Saitama, 350-0851, Japan
    Enrolling by invitation
  • Matsudakai Tsurugaya Clinic, Internal medicine
    Sendai-shi, Miyagi, 983-0824, Japan
    Enrolling by invitation
  • Nagahama City Hospital_Nephrology and Metabolism
    Shiga, 526-8580, Japan
    Enrolling by invitation
  • Yamauchi Naika_Internal Medicine
    Shimane, 694-0041, Japan
    Enrolling by invitation
  • Yamane Hospital
    Shimane, 697-0062, Japan
    Recruiting
  • Juntendo University Shizuoka Hospital_Diabetes and Endocrinology
    Shizuoka, 410-2295, Japan
    Enrolling by invitation
  • Kikuchi Medical Clinic
    Shizuoka, 430-0802, Japan
    Recruiting
  • Higashi Diabetes and Cardiovascular Clinic, Internal
    Tamana-shi, Kumamoto, 865 0016, Japan
    Enrolling by invitation
  • Oyama East Clinic_Internal Medicine
    Tochigi, 323-0022, Japan
    Enrolling by invitation
  • Nagasaki Hospital_Internal Medicine
    Tochigi, 326-0053, Japan
    Enrolling by invitation
  • Ooshima Clinic
    Tokushima, 770-0022, Japan
    Enrolling by invitation
  • Kudanzaka Hospital_Internal Medicine
    Tokyo, 102-0074, Japan
    Enrolling by invitation
  • Aoi Clinic_Diabetes and Internal Medicine
    Tokyo, 105-0004, Japan
    Enrolling by invitation
  • The Jikei University Hospital Dept of Diabetes, Metabolic
    Tokyo, 105-8471, Japan
    Enrolling by invitation

Showing the first 100 of 116 sites. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: Yes — According to the Novo Nordisk disclosure commitment on novonordisk-trials.com

Data sharing details ↗ · novonordisk-trials.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2025 (actual). Primary completion is estimated for Jul 2027, 27 months after the start.

Of 50 industry-sponsored observational studies under Diabetes Mellitus, Type 1, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 42. This study's planned 27 months is above that.

Counting every sponsor, half of 298 studies reached it within 28 months; a quarter within 12 and three quarters within 69.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 29, 2025
First posted
Feb 4, 2025
StartActual
Apr 15, 2025
Primary completionEst.
Jul 31, 2027
CompletionEst.
Jan 31, 2028
Last update
Aug 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06807190
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Feb 4, 2025
Start date
Apr 15, 2025
Primary completion
Jul 31, 2027 (estimated)
Completion
Jan 31, 2028 (estimated)
Last update
Aug 27, 2026

Study contacts

Novo Nordisk
Contact
clinicaltrials@novonordisk.com
(+1) 866-867-7178
Clinical Transparency (dept. 2834)
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion